• Isabel García-López, Lourdes Chocarro-González, Irene Martín-Romero, Juan Manuel Vázquez-Sánchez, María Avilés-Martínez, and Ricardo Martino-Alba.
• Pharmacy Department (I.G-L., I.M-R.), Hospital Infantil Universitario Niño Jesús, Madrid, Spain. Electronic address: iglopez@salud.madrid.org.
• J Pain Symptom Manage. 2023 Sep 1; 66 (3): e319e326e319-e326.

ContextThe subcutaneous route is a useful alternative for drug administration in palliative care. Although there is scientific evidence on its use in adult patients, the literature in pediatric palliative care is almost nonexistent.ObjectivesTo describe the experience of a pediatric palliative care unit (PPCU) with in-home subcutaneous drug administration symptom control.MethodsProspective observational study of patients receiving home-based subcutaneous treatment administered as part of a PPCU treatment regimen over 16 months. Analysis includes demographic and clinical variables and treatment received.ResultsFifty-four different subcutaneous lines were inserted in the 15 patients included, mainly in the thigh (85.2%). The median time of needle in situ was 5.5 days (range: 1-36 days). A single drug was administered in 55.7% of treatments. The most frequently used drugs were morphine chloride (82%) and midazolam (55.7%). Continuous subcutaneous infusion was the predominant administration route (96.7%), with infusion rates oscillating between 0.1 mL/h and 1.5 mL/h. A statistically significant relationship was found between the maximum infusion rate and induration onset. Of the 54 lines placed, 29 (53.7%) had an associated complication requiring line removal. The primary cause for removal was insertion-site induration (46.3%). Subcutaneous lines were mainly used to manage pain, dyspnea, and epileptic seizures.ConclusionIn the pediatric palliative care patients studied, the subcutaneous route is most frequently used for administering morphine and midazolam in continuous infusion. The main complication was induration, especially with longer dwell times or higher infusion rates. However, further studies are required to optimize management and prevent complications.Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

15 keywords...

hide…